Loading...

UroGen Pharma

Nasdaq:URGN
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
URGN
Nasdaq
$662M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The last earnings update was 74 days ago. More info.


Add to Portfolio Compare Print
URGN Share Price and Events
7 Day Returns
-1.8%
NasdaqGM:URGN
-1%
US Biotechs
-1.2%
US Market
1 Year Returns
-32.7%
NasdaqGM:URGN
-11.9%
US Biotechs
3.3%
US Market
URGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
UroGen Pharma (URGN) -1.8% -7.8% -15.6% -32.7% - -
US Biotechs -1% -3.6% -0.7% -11.9% 5.4% 7.4%
US Market -1.2% 0.8% 0.9% 3.3% 35.9% 41.7%
1 Year Return vs Industry and Market
  • URGN underperformed the Biotechs industry which returned -11.9% over the past year.
  • URGN underperformed the Market in United States of America which returned 3.3% over the past year.
Price Volatility
URGN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is UroGen Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of UroGen Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for UroGen Pharma.

NasdaqGM:URGN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:URGN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.33
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.328 (1 + (1- 21%) (0.48%))
1.223
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.223 * 5.96%)
10.02%

Discounted Cash Flow Calculation for NasdaqGM:URGN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for UroGen Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:URGN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.02%)
2020 -82.67 Analyst x3 -75.14
2021 -19.33 Analyst x3 -15.97
2022 -41.00 Analyst x1 -30.79
2023 133.50 Analyst x2 91.12
2024 219.39 Est @ 64.34% 136.10
2025 319.99 Est @ 45.86% 180.43
2026 425.33 Est @ 32.92% 217.98
2027 526.82 Est @ 23.86% 245.40
2028 619.13 Est @ 17.52% 262.14
2029 700.14 Est @ 13.08% 269.44
Present value of next 10 years cash flows $1,280.71
NasdaqGM:URGN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $700.14 × (1 + 2.73%) ÷ (10.02% – 2.73%)
$9,866.01
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $9,866.01 ÷ (1 + 10.02%)10
$3,796.80
NasdaqGM:URGN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,280.71 + $3,796.80
$5,077.50
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,077.50 / 20.79
$244.21
NasdaqGM:URGN Discount to Share Price
Calculation Result
Value per share (USD) From above. $244.21
Current discount Discount to share price of $31.86
= -1 x ($31.86 - $244.21) / $244.21
87%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price UroGen Pharma is available for.
Intrinsic value
>50%
Share price is $31.86 vs Future cash flow value of $244.21
Current Discount Checks
For UroGen Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • UroGen Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • UroGen Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for UroGen Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are UroGen Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:URGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-4.99
NasdaqGM:URGN Share Price ** NasdaqGM (2019-07-19) in USD $31.86
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.44x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.86x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of UroGen Pharma.

NasdaqGM:URGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:URGN Share Price ÷ EPS (both in USD)

= 31.86 ÷ -4.99

-6.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UroGen Pharma is loss making, we can't compare its value to the US Biotechs industry average.
  • UroGen Pharma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does UroGen Pharma's expected growth come at a high price?
Raw Data
NasdaqGM:URGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
49.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 0.79x
United States of America Market PEG Ratio Median Figure of 2,119 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for UroGen Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on UroGen Pharma's assets?
Raw Data
NasdaqGM:URGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $11.54
NasdaqGM:URGN Share Price * NasdaqGM (2019-07-19) in USD $31.86
United States of America Biotechs Industry PB Ratio Median Figure of 437 Publicly-Listed Biotechs Companies 2.93x
United States of America Market PB Ratio Median Figure of 5,248 Publicly-Listed Companies 1.79x
NasdaqGM:URGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:URGN Share Price ÷ Book Value per Share (both in USD)

= 31.86 ÷ 11.54

2.76x

* Primary Listing of UroGen Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UroGen Pharma is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess UroGen Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. UroGen Pharma has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is UroGen Pharma expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
49.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is UroGen Pharma expected to grow at an attractive rate?
  • UroGen Pharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • UroGen Pharma's earnings growth is expected to exceed the United States of America market average.
  • UroGen Pharma's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:URGN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:URGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 49.3%
NasdaqGM:URGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 65.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:URGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:URGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 292 257 6 5
2022-12-31 224 138 9 6
2021-12-31 100 -25 -75 8
2020-12-31 44 -63 -92 9
2019-12-31 0 -77 -106 9
NasdaqGM:URGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 -46 -84
2018-12-31 1 -37 -76
2018-09-30 1 -33 -62
2018-06-30 9 -21 -42
2018-03-31 9 -16 -30
2017-12-31 8 -10 -21
2017-09-30 25 10 2
2017-06-30 18 4 -7
2017-03-31 18 4 -4
2016-12-31 18 4 -4
2016-09-30 -11 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • UroGen Pharma's earnings are expected to grow significantly at over 20% yearly.
  • UroGen Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:URGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from UroGen Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:URGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.68 8.37 -2.10 4.00
2022-12-31 0.59 7.74 -4.66 5.00
2021-12-31 -3.34 -0.25 -5.33 5.00
2020-12-31 -4.69 -3.26 -6.33 7.00
2019-12-31 -5.33 -4.82 -5.83 8.00
NasdaqGM:URGN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -4.99
2018-12-31 -4.80
2018-09-30 -4.04
2018-06-30 -2.86
2018-03-31 -2.33
2017-12-31 -2.14
2017-09-30 0.23
2017-06-30 -1.67
2017-03-31 -1.85
2016-12-31 -1.91
2016-09-30 -10.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if UroGen Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess UroGen Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
UroGen Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has UroGen Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare UroGen Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • UroGen Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare UroGen Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare UroGen Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
UroGen Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from UroGen Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:URGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.65 -83.72 38.71 36.64
2018-12-31 1.13 -75.66 32.07 34.53
2018-09-30 1.46 -62.03 25.06 30.57
2018-06-30 8.98 -41.79 21.91 28.28
2018-03-31 8.62 -30.19 14.01 23.66
2017-12-31 8.16 -20.83 8.81 18.70
2017-09-30 25.36 1.56 6.60 14.31
2017-06-30 17.55 -6.75 7.64 11.56
2017-03-31 17.55 -4.27 6.39 10.26
2016-12-31 17.53 -4.41 6.42 10.29
2016-09-30 -24.14 6.07 13.99
2016-03-31 -15.56 2.61 11.37
2015-12-31 -13.54 1.90 10.52
2015-09-30 -7.39 1.29 5.35
2014-12-31 -4.56 0.89 3.48
2013-12-31 -3.31 1.06 2.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if UroGen Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if UroGen Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if UroGen Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess UroGen Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
UroGen Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is UroGen Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up UroGen Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • UroGen Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • UroGen Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of UroGen Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • UroGen Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from UroGen Pharma Company Filings, last reported 3 months ago.

NasdaqGM:URGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 239.59 0.00 246.69
2018-12-31 90.09 0.00 101.32
2018-09-30 103.58 0.00 109.48
2018-06-30 113.55 0.00 119.11
2018-03-31 123.87 0.00 127.46
2017-12-31 68.52 0.00 73.00
2017-09-30 76.26 0.00 79.17
2017-06-30 74.07 0.00 77.09
2017-03-31 19.92 0.00 21.36
2016-12-31 19.92 0.00 21.36
2016-09-30 5.44 0.00 8.21
2016-03-31 14.01 0.00 15.07
2015-12-31 17.15 0.00 17.98
2015-09-30 1.85 0.00 1.58
2014-12-31 3.47 0.00 3.87
2013-12-31 2.74 0.00 3.04
  • UroGen Pharma has no debt.
  • UroGen Pharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • UroGen Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • UroGen Pharma has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 85% each year.
X
Financial health checks
We assess UroGen Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. UroGen Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is UroGen Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from UroGen Pharma dividends. Estimated to be 0% next year.
If you bought $2,000 of UroGen Pharma shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate UroGen Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate UroGen Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:URGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 18 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:URGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as UroGen Pharma has not reported any payouts.
  • Unable to verify if UroGen Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of UroGen Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as UroGen Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of UroGen Pharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess UroGen Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can UroGen Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. UroGen Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of UroGen Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Liz Barrett
AGE 57
TENURE AS CEO 0.5 years
CEO Bio

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology at Novartis AG since February 1, 2018 until December 31, 2018. Ms. Barrett served as the Regional President of US Oncology Business Unit at Pfizer Inc. since March 23, 2009. Ms. Barrett has over 30 years of management expertise and a proven track record in building profitable organizations, working in multi-national companies with international experience and launching and expanding new businesses. She served as Vice President & General Manager for Oncology Business Unit at Cephalon Inc., where she successfully launched it into oncology in an integrated business unit. Ms. Barrett oversaw the marketing, sales and medical affairs organizations and was responsible for developing the short and long term plans to build an oncology business. Her previous oncology experience also includes managing Johnson & Johnson's cancer therapeutics business and overseeing its new business development and licensing and acquisitions. At Johnson & Johnson she also served as Worldwide Vice President of Sales and Marketing for Veridex, LLC and Vice President of the Critical Care and Surgery Franchise for Ortho Biotech, Inc. She is Director of Sage Therapeutics, Inc. since January 22, 2019. Ms. Barrett has received numerous awards from industry organizations including TWIN (Tribute to Women in the Industry), DTC Marketer of the Year, VP Sales/Marketing Award, HBA Rising Star, Women's Leadership Initiative Ambassador and Outstanding Marketer of the Year. She started her career at Kraft Foods Group Inc. She holds a Bachelor of Science in Business Administration from the University of Louisiana in Lafayette, Louisiana and a Masters in Business Administration-Marketing from St. Joseph's University in Philadelphia, Pennsylvania.

CEO Compensation
  • Insufficient data for Liz to compare compensation growth.
  • Insufficient data for Liz to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the UroGen Pharma management team in years:

1.2
Average Tenure
54.5
Average Age
  • The average tenure for the UroGen Pharma management team is less than 2 years, this suggests a new team.
Management Team

Liz Barrett

TITLE
President
AGE
57
TENURE
0.5 yrs

Peter Pfreundschuh

TITLE
CFO & Secretary
AGE
50
TENURE
0.9 yrs

Stephen Mullennix

TITLE
Chief Operating Officer
TENURE
1.4 yrs

Kate Bechtold

TITLE
Director of Corporate Communications & Investor Relations
TENURE
1.5 yrs

Sari Prutchi-Sagiv

TITLE
Marketing Director

Mark Schoenberg

TITLE
Chief Medical Officer
AGE
61
TENURE
1.6 yrs

Elyse Seltzer

TITLE
Senior Vice President of Clinical Development
AGE
54
TENURE
1.6 yrs

Woody Bryan

TITLE
Senior Vice President of Business Development
AGE
55
TENURE
0.8 yrs

Marina Konorty

TITLE
Chief Chemist

Gil Hakim

TITLE
Consultant
AGE
49
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the UroGen Pharma board of directors in years:

2.3
Average Tenure
63
Average Age
  • The average tenure for the UroGen Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Arie Belldegrun

TITLE
Chairman of the Board
AGE
70
TENURE
16.6 yrs

Liz Barrett

TITLE
President
AGE
57
TENURE
0.5 yrs

Herbert Lepor

TITLE
Chairman of Scientific Advisory Board

Kate Falberg

TITLE
Director
AGE
58
TENURE
2.3 yrs

Cindy Butitta

TITLE
Director
AGE
65
TENURE
1.8 yrs

Fred Witjes

TITLE
Member of Scientific Advisory Board

Jack Baniel

TITLE
Member of Scientific Advisory Board

Ran Nussbaum

TITLE
Director
AGE
46
TENURE
6.2 yrs

Stuart Holden

TITLE
Director
AGE
76
TENURE
3.6 yrs

Fred Cohen

TITLE
Director
AGE
63
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
22. Mar 19 Buy Mark Schoenberg Individual 21. Mar 19 21. Mar 19 272 $37.01 $10,066
08. Mar 19 Sell Mark Schoenberg Individual 06. Mar 19 06. Mar 19 -949 $37.30 $-35,398
X
Management checks
We assess UroGen Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. UroGen Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

A Look At UroGen Pharma Ltd.'s (NASDAQ:URGN) Exceptional Fundamentals

By this I mean, I look at stocks holistically, from their financial health to their future outlook. … (NASDAQ:URGN), it is a company with strong financial health as well as an optimistic future outlook. … Flawless balance sheet with high growth potential One reason why investors are attracted to URGN is its notable earnings growth potential in the near future of 49%.

Simply Wall St -

Could UroGen Pharma Ltd.'s (NASDAQ:URGN) Investor Composition Influence The Stock Price?

UroGen Pharma is a smaller company with a market capitalization of US$746m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for UroGen Pharma NasdaqGM:URGN Ownership Summary, June 6th 2019 What Does The Institutional Ownership Tell Us About UroGen Pharma? … Insider Ownership Of UroGen Pharma The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Does The UroGen Pharma Ltd. (NASDAQ:URGN) Share Price Fall With The Market?

Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

How Much Are UroGen Pharma Ltd. (NASDAQ:URGN) Insiders Taking Off The Table?

So we'll take a look at whether insiders have been buying or selling shares in UroGen Pharma Ltd. … UroGen Pharma Insider Transactions Over The Last Year. … In the last twelve months, the biggest single sale by an insider was when the , Moshe Arkin, sold US$12m worth of shares at a price of US$62.56 per share.

Simply Wall St -

Imagine Owning UroGen Pharma (NASDAQ:URGN) And Wondering If The 37% Share Price Slide Is Justified

Because UroGen Pharma hasn't been listed for many years, the market is still learning about how the business performs. … It seems likely some shareholders believe that UroGen Pharma has the funding to invent a new product before too long. … When it last reported its balance sheet in December 2018, UroGen Pharma had net cash of US$88m.

Simply Wall St -

UroGen Pharma Ltd. (NASDAQ:URGN) Is Trading At A 31.84% Discount

Help shape the future of investing tools and you could win a $250 gift card! … by taking the expected future cash flows and discounting them to today's value. … Discounted Cash Flows (DCF)

Simply Wall St -

How Much Are UroGen Pharma Ltd. (NASDAQ:URGN) Insiders Taking Off The Table?

The Last 12 Months Of Insider Transactions At UroGen Pharma. … In the last twelve months, the biggest single sale by an insider was when Moshe Arkin sold US$12m worth of shares at a price of US$62.56 per share. … Moshe Arkin was the only individual insider to sell shares in the last twelve months

Simply Wall St -

Can We See Significant Insider Ownership On The UroGen Pharma Ltd. (NASDAQ:URGN) Share Register?

The big shareholder groups in UroGen Pharma Ltd. … With a market capitalization of US$727m, UroGen Pharma is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for UroGen Pharma

Simply Wall St -

How Financially Strong Is UroGen Pharma Ltd (NASDAQ:URGN)?

UroGen Pharma Ltd (NASDAQ:URGN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Does URGN's growth rate justify its decision for financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Is UroGen Pharma Ltd's (NASDAQ:URGN) Balance Sheet A Threat To Its Future?

UroGen Pharma Ltd (NASDAQ:URGN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is URGN will have to follow strict debt obligations which will reduce its financial flexibility. … Is URGN growing fast enough to value financial flexibility over lower cost of capital

Simply Wall St -

Company Info

Description

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company’s lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.

Details
Name: UroGen Pharma Ltd.
URGN
Exchange: NasdaqGM
Founded: 2004
$662,415,437
20,791,445
Website: http://www.urogen.com
Address: UroGen Pharma Ltd.
499 Park Avenue,
New York,
New York, 10014,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM URGN Ordinary Shares Nasdaq Global Market US USD 04. May 2017
DB UR8 Ordinary Shares Deutsche Boerse AG DE EUR 04. May 2017
LSE 0XOD Ordinary Shares London Stock Exchange GB USD 04. May 2017
Number of employees
Current staff
Staff numbers
70
UroGen Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/22 03:27
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/18
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.